1887

Journal of General Virology header logo

Volume 98, Issue 7

Evolution of cross-neutralizing antibodies and mapping epitope specificity in plasma of chronic HIV-1-infected antiretroviral therapy-naïve children from India Free

Abstract

Delineating the factors leading to the development of broadly neutralizing antibodies (bnAbs) during natural HIV-1 infection and dissecting their epitope specificities generates useful information for vaccine design. This is the first longitudinal study to assess the plasma-neutralizing antibody response and neutralizing determinants in HIV-1-infected children from India. We enrolled 26 and followed up 20 antiretroviral therapy (ART)-naïve, asymptomatic, chronic HIV-1-infected children. Five (19.2 %) baseline and 10 (50 %) follow-up plasma samples neutralized ≥50 % of subtypes A, B and C tier 2 viruses at an ID titre ≥150. A modest improvement in neutralization breadth and potency was observed with time. At baseline, subtype C-specific neutralization predominated =0.026); interestingly, follow-up samples exhibited cross-neutralizing activity. Epitope mapping revealed V3C reactive antibodies with significantly increased Max binding titres in follow-up samples from five infected children; patient #4's plasma antibodies exhibited V3-directed neutralization. A salient observation was the presence of CD4 binding site (CD4bs)-specific NAbs in patient #18 that improved with time (1.76-fold). The RSC3 wild-type (RSC3WT) protein-depleted plasma eluate of patient #18 demonstrated a more than 50% ID decrease in neutralization capacity against five HIV-1 pseudoviruses. Further, the presence of CD4bs-neutralizing determinants in patient #18's plasma was confirmed by the neutralizing activity demonstrated by the CD4bs-directed IgG fraction purified from this plasma, and competition with sCD4 against JRFLgp120, identifying this paediatric donor as a potential candidate for the isolation of CD4bs-directed bnAbs. Overall, we observed a relative increase in plasma-neutralizing activity with time in HIV-1-infected children, which suggests that the bnAbs evolve.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): CD4bs and anti-V3 plasma antibodies , follow-up , HIV-1-infected children , neutralization , pseudoviruses and vaccine
© 2017 The Authors
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000824
2017-07-01
2024-04-25
Loading full text...

Full text loading...

/deliver/fulltext/jgv/98/7/1879.html?itemId=/content/journal/jgv/10.1099/jgv.0.000824&mimeType=html&fmt=ahah

References

  1. Doria-Rose NA. HIV neutralizing antibodies: clinical correlates and implications for vaccines. J Infect Dis 2010; 201:981–983 [View Article][PubMed]
     [Google Scholar]
  2. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 2008; 82:12449–12463 [View Article][PubMed]
     [Google Scholar]
  3. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6:200–206 [View Article][PubMed]
     [Google Scholar]
  4. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012; 482:89–93 [View Article][PubMed]
     [Google Scholar]
  5. Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA, Wang T, Xu W et al. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS 2003; 17:301–309 [View Article][PubMed]
     [Google Scholar]
  6. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009; 15:951–954 [View Article][PubMed]
     [Google Scholar]
  7. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001; 75:8340–8347 [View Article][PubMed]
     [Google Scholar]
  8. Gaschen B, Taylor J, Yusim K, Foley B, Gao F et al. Diversity considerations in HIV-1 vaccine selection. Science 2002; 296:2354–2360 [View Article][PubMed]
     [Google Scholar]
  9. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998; 280:1884–1888 [View Article][PubMed]
     [Google Scholar]
  10. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002; 420:678–682 [View Article][PubMed]
     [Google Scholar]
  11. Wei X, Decker JM, Wang S, Hui H, Kappes JC et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422:307–312 [View Article][PubMed]
     [Google Scholar]
  12. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654–665 [View Article][PubMed]
     [Google Scholar]
  13. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661–1671 [View Article][PubMed]
     [Google Scholar]
  14. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881–1893 [View Article][PubMed]
     [Google Scholar]
  15. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 2013; 369:2083–2092 [View Article][PubMed]
     [Google Scholar]
  16. Gilbert PB, Ackers ML, Berman PW, Francis DP, Popovic V et al. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J Infect Dis 2005; 192:974–983 [View Article][PubMed]
     [Google Scholar]
  17. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol 2011; 85:4828–4840 [View Article][PubMed]
     [Google Scholar]
  18. Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F et al. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 2007; 81:6187–6196 [View Article][PubMed]
     [Google Scholar]
  19. Overbaugh J, Morris L. The antibody response against HIV-1. Cold Spring Harb Perspect Med 2012; 2:a007039 [View Article][PubMed]
     [Google Scholar]
  20. Simek MD, Rida W, Priddy FH, Pung P, Carrow E et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 2009; 83:7337–7348 [View Article][PubMed]
     [Google Scholar]
  21. Doria-Rose NA, Klein RM, Daniels MG, O'Dell S, Nason M et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol 2010; 84:1631–1636 [View Article][PubMed]
     [Google Scholar]
  22. Beirnaert E, Nyambi P, Willems B, Heyndrickx L, Colebunders R et al. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates. J Med Virol 2000; 62:14–24 [View Article][PubMed]
     [Google Scholar]
  23. Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E et al. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 2008; 82:11651–11668 [View Article][PubMed]
     [Google Scholar]
  24. Richardson BA, Mbori-Ngacha D, Lavreys L, John-Stewart GC, Nduati R et al. Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection. J Virol 2003; 77:7120–7123 [View Article][PubMed]
     [Google Scholar]
  25. Becquet R, Marston M, Dabis F, Moulton LH, Gray G et al. Children who acquire HIV infection perinatally are at higher risk of early death than those acquiring infection through breastmilk: a meta-analysis. PLoS One 2012; 7:e28510 [View Article][PubMed]
     [Google Scholar]
  26. Ferrand RA, Corbett EL, Wood R, Hargrove J, Ndhlovu CE et al. AIDS among older children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic. AIDS 2009; 23:2039–2046 [View Article][PubMed]
     [Google Scholar]
  27. Morgan D, Mahe C, Mayanja B, Okongo JM, Lubega R et al. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries?. AIDS 2002; 16:597–603 [View Article][PubMed]
     [Google Scholar]
  28. Pananghat AN, Aggarwal H, Prakash SS, Makhdoomi MA, Singh R et al. IL-8 alterations in HIV-1 infected children with disease progression. Medicine 2016; 95:e3734 [View Article][PubMed]
     [Google Scholar]
  29. Ssewanyana I, Elrefaei M, Dorsey G, Ruel T, Jones NG et al. Profile of T cell immune responses in HIV-infected children from Uganda. J Infect Dis 2007; 196:1667–1670 [View Article][PubMed]
     [Google Scholar]
  30. Prakash SS, Andrabi R, Kumar R, Lodha R, Kabra SK et al. Antibodies that cross-neutralize the tier-2 pseudoviruses are produced in antiretroviral-naïve HIV-1-infected children from Northern India. Arch Virol 2012; 157:1797–1801 [View Article][PubMed]
     [Google Scholar]
  31. Prakash SS, Chaudhary AK, Lodha R, Kabra SK, Vajpayee M et al. Efficient neutralization of primary isolates by the plasma from HIV-1 infected Indian children. Viral Immunol 2011; 24:409–413 [View Article][PubMed]
     [Google Scholar]
  32. Goo L, Chohan V, Nduati R, Overbaugh J. Early development of broadly neutralizing antibodies in HIV-1-infected infants. Nat Med 2014; 20:655–658 [View Article][PubMed]
     [Google Scholar]
  33. Simonich CA, Williams KL, Verkerke HP, Williams JA, Nduati R et al. HIV-1 neutralizing antibodies with limited hypermutation from an infant. Cell 2016; 166:77–87 [View Article][PubMed]
     [Google Scholar]
  34. Barin F, Jourdain G, Brunet S, Ngo-Giang-Huong N, Weerawatgoompa S et al. Revisiting the role of neutralizing antibodies in mother-to-child transmission of HIV-1. J Infect Dis 2006; 193:1504–1511 [View Article][PubMed]
     [Google Scholar]
  35. Kittinunvorakoon C, Morris MK, Neeyapun K, Jetsawang B, Buehring GC et al. Mother to child transmission of HIV-1 in a Thai population: role of virus characteristics and maternal humoral immune response. J Med Virol 2009; 81:768–778 [View Article][PubMed]
     [Google Scholar]
  36. Lynch JB, Nduati R, Blish CA, Richardson BA, Mabuka JM et al. The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection. J Virol 2011; 85:5252–5261 [View Article][PubMed]
     [Google Scholar]
  37. Omenda MM, Milligan C, Odem-Davis K, Nduati R, Richardson BA et al. Evidence for efficient vertical transfer of maternal HIV-1 envelope-specific neutralizing antibodies but no association of such antibodies with reduced infant infection. J Acquir Immune Defic Syndr 2013; 64:163–166 [View Article][PubMed]
     [Google Scholar]
  38. Chaillon A, Wack T, Braibant M, Mandelbrot L, Blanche S et al. The breadth and titer of maternal HIV-1-specific heterologous neutralizing antibodies are not associated with a lower rate of mother-to-child transmission of HIV-1. J Virol 2012; 86:10540–10546 [View Article][PubMed]
     [Google Scholar]
  39. Wu X, Parast AB, Richardson BA, Nduati R, John-Stewart G et al. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol 2006; 80:835–844 [View Article][PubMed]
     [Google Scholar]
  40. Decamp A, Hraber P, Bailer RT, Seaman MS, Ochsenbauer C et al. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2014; 88:2489–2507 [View Article][PubMed]
     [Google Scholar]
  41. Khan L, Makhdoomi MA, Kumar S, Nair A, Andrabi R et al. Identification of CD4-binding site dependent plasma neutralizing antibodies in an HIV-1 infected Indian individual. PLoS One 2015; 10:e0125575 [View Article][PubMed]
     [Google Scholar]
  42. Makhdoomi MA, Singh D, Nair Pananghat A, Lodha R, Kabra SK et al. Neutralization resistant HIV-1 primary isolates from antiretroviral naïve chronically infected children in India. Virology 2016; 499:105–113 [View Article][PubMed]
     [Google Scholar]
  43. Tobin NH, Aldrovandi GM. Immunology of pediatric HIV infection. Immunol Rev 2013; 254:143–169 [View Article][PubMed]
     [Google Scholar]
  44. Tobin NH, Aldrovandi GM. Are infants unique in their ability to be “functionally cured” of HIV-1?. Curr HIV/AIDS Rep 2014; 11:1–10 [View Article][PubMed]
     [Google Scholar]
  45. Lehman DA, Farquhar C. Biological mechanisms of vertical human immunodeficiency virus (HIV-1) transmission. Rev Med Virol 2007; 17:381–403 [View Article][PubMed]
     [Google Scholar]
  46. Subbarao S, Schochetman G. Genetic variability of HIV-1. AIDS 1996; 10:S13–S24 [View Article][PubMed]
     [Google Scholar]
  47. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006; 20:W13–W23 [View Article][PubMed]
     [Google Scholar]
  48. Hemelaar J, Gouws E, Ghys PD, Osmanov S. WHO-UNAIDS Network for HIV Isolation and Characterisation Global trends in molecular epidemiology of HIV-1 during 2000–2007. AIDS 2011; 25:679–689 [View Article][PubMed]
     [Google Scholar]
  49. Walker BD, Korber BT. Immune control of HIV: the obstacles of HLA and viral diversity. Nat Immunol 2001; 2:473–475 [View Article][PubMed]
     [Google Scholar]
  50. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393:648–659 [View Article][PubMed]
     [Google Scholar]
  51. Landais E, Huang X, Havenar-Daughton C, Murrell B, Price MA et al. Broadly neutralizing antibody responses in a large longitudinal sub-Saharan HIV primary infection cohort. PLoS Pathog 2016; 12:e1005369 [View Article][PubMed]
     [Google Scholar]
  52. Andrabi R, Kumar R, Bala M, Nair A, Prakash SS et al. Envelope diversity, characteristics of V3 region and predicted co-receptor usage of human immunodeficiency viruses infecting north Indians. J Microbiol 2012; 50:869–873 [View Article][PubMed]
     [Google Scholar]
  53. Neogi U, Bontell I, Shet A, de Costa A, Gupta S et al. Molecular epidemiology of HIV-1 subtypes in India: origin and evolutionary history of the predominant subtype C. PLoS One 2012; 7:e39819 [View Article][PubMed]
     [Google Scholar]
  54. Andrabi R, Bala M, Kumar R, Wig N, Hazarika A et al. Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India. PLoS One 2012; 7:e43704 [View Article][PubMed]
     [Google Scholar]
  55. Lakhashe SK, Kulkarni SS, Thakar MR, Ghate MV, Paranjape RS. Extensive cross-reactive neutralizing antibody response in Indian patients with limited genetic diversity of HIV-1. Virology 2007; 359:295–301 [View Article][PubMed]
     [Google Scholar]
  56. Hu X, Hong K, Zhao C, Zheng Y, Ma L et al. Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy. J Gen Virol 2012; 93:2267–2278 [View Article][PubMed]
     [Google Scholar]
  57. Mascola JR, Louder MK, Surman SR, Vancott TC, Yu XF et al. Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Res Hum Retroviruses 1996; 12:1319–1328 [View Article][PubMed]
     [Google Scholar]
  58. Fraser C, Hollingsworth TD, Chapman R, de Wolf F, Hanage WP. Variation in HIV-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis. Proc Natl Acad Sci USA 2007; 104:17441–17446 [View Article][PubMed]
     [Google Scholar]
  59. Goujard C, Bonarek M, Meyer L, Bonnet F, Chaix ML et al. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 2006; 42:709–715 [View Article][PubMed]
     [Google Scholar]
  60. Piantadosi A, Panteleeff D, Blish CA, Baeten JM, Jaoko W et al. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol 2009; 83:10269–10274 [View Article][PubMed]
     [Google Scholar]
  61. Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 2009; 83:757–769 [View Article][PubMed]
     [Google Scholar]
  62. Pancera M, McLellan JS, Wu X, Zhu J, Changela A et al. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol 2010; 84:8098–8110 [View Article][PubMed]
     [Google Scholar]
  63. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010; 329:811–817 [View Article][PubMed]
     [Google Scholar]
  64. Andrabi R, Choudhary AK, Bala M, Kalra R, Prakash SS et al. Relative reactivity of HIV-1 polyclonal plasma antibodies directed to V3 and MPER regions suggests immunodominance of V3 over MPER and dependence of high anti-V3 antibody titers on virus persistence. Arch Virol 2011; 156:1787–1794 [View Article][PubMed]
     [Google Scholar]
  65. Choudhary AK, Andrabi R, Prakash SS, Kumar R, Choudhury SD et al. Neutralization potential of the plasma of HIV-1 infected Indian patients in the context of anti-V3 antibody content and antiretroviral therapy. [corrected]. J Microbiol 2012; 50:149–154 [View Article][PubMed]
     [Google Scholar]
  66. Spenlehauer C, Saragosti S, Fleury HJ, Kirn A, Aubertin AM et al. Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1. J Virol 1998; 72:9855–9864[PubMed]
     [Google Scholar]
  67. Cohen YZ, Lavine CL, Miller CA, Garrity J, Carey BR et al. Glycan-Dependent neutralizing antibodies are frequently elicited in individuals chronically infected with HIV-1 clade B or C. AIDS Res Hum Retroviruses 2015; 31:1192–1201 [View Article][PubMed]
     [Google Scholar]
  68. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010; 329:856–861 [View Article][PubMed]
     [Google Scholar]
  69. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011; 333:1633–1637 [View Article][PubMed]
     [Google Scholar]
  70. Veselinovic M, Neff CP, Mulder LR, Akkina R. Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model. Virology 2012; 432:505–510 [View Article][PubMed]
     [Google Scholar]
  71. Pegu A, Yang ZY, Boyington JC, Wu L, Ko SY et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med 2014; 6:243ra88 [View Article][PubMed]
     [Google Scholar]
  72. Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013; 503:224–228 [View Article][PubMed]
     [Google Scholar]
  73. Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013; 503:277–280 [View Article][PubMed]
     [Google Scholar]
  74. Bolton DL, Pegu A, Wang K, McGinnis K, Nason M et al. Human immunodeficiency virus type 1 monoclonal antibodies suppress acute simian-human immunodeficiency virus viremia and limit seeding of cell-associated viral reservoirs. J Virol 2015; 90:1321–1332 [View Article][PubMed]
     [Google Scholar]
  75. Scheid JF, Horwitz JA, Bar-On Y, Kreider EF, Lu CL et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 2016; 535:556–560 [View Article][PubMed]
     [Google Scholar]
  76. Lynch RM, Boritz E, Coates EE, DeZure A, Madden P et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med 2015; 7:319ra206 [View Article][PubMed]
     [Google Scholar]
  77. Ledgerwood JE, Coates EE, Yamshchikov G, Saunders JG, Holman L et al. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol 2015; 182:289–301 [View Article][PubMed]
     [Google Scholar]
  78. Khouri YF, Mcintosh K, Cavacini L, Posner M, Pagano M et al. Vertical transmission of HIV-1. Correlation with maternal viral load and plasma levels of CD4 binding site anti-gp120 antibodies. J Clin Invest 1995; 95:732–737 [View Article][PubMed]
     [Google Scholar]
  79. Lynch RM, Tran L, Louder MK, Schmidt SD, Cohen M et al. The development of CD4 binding site antibodies during HIV-1 infection. J Virol 2012; 86:7588–7595 [View Article][PubMed]
     [Google Scholar]
  80. Maitra A, Singh B, Banu S, Deshpande A, Robbins K et al. Subtypes of HIV type 1 circulating in India: partial envelope sequences. AIDS Res Hum Retroviruses 1999; 15:941–944 [View Article][PubMed]
     [Google Scholar]
  81. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 2010; 84:1439–1452 [View Article][PubMed]
     [Google Scholar]
  82. Prakash SS, Andrabi R, Kumar R, Kabra SK, Lodha R et al. Binding antibody responses to the immunogenic regions of viral envelope in HIV-1-infected Indian children. Viral Immunol 2011; 24:463–469 [View Article][PubMed]
     [Google Scholar]
  83. Gach JS, Quendler H, Tong T, Narayan KM, Du SX et al. A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1. PLoS One 2013; 8:e72054 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000824
Loading
Evolution of cross-neutralizing antibodies and mapping epitope specificity in plasma of chronic HIV-1-infected antiretroviral therapy-naïve children from India
J. Gen. Virol. 98, 1879 (2017); https://doi.org/10.1099/jgv.0.000824
/content/journal/jgv/10.1099/jgv.0.000824
/content/journal/jgv/10.1099/jgv.0.000824
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error